ArticleHuman vaccines & immunotherapeutics2016
Seropositivity of Varicella zoster virus in vaccinated Korean children and MAV vaccine group.
Article in Human vaccines & immunotherapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 22 citations in OpenAlex.
- Safety, immunogenicity, and effectiveness of the MAV/06 varicella vaccine: A comprehensive review of a new strain vaccine.Human vaccines & immunotherapeutics · 2026Review
- Seroepidemiological Study of Varicella Zoster Virus in Korea, 2023.Journal of Korean medical science · 2026Article
- Research Progress on Varicella-Zoster Virus Vaccines.Vaccines · 2025Review
- Seroprevalence comparison of different varicella vaccines among Turkish children.Human vaccines & immunotherapeutics · 2022Article
- Estimation of single-dose varicella vaccine effectiveness in South Korea using mathematical modeling.Human vaccines & immunotherapeutics · 2022Article
- Letter to the Editor: Effectiveness of the Varicella Vaccine Among Korean Children: Suggestions for Future Research.Journal of Korean medical science · 2022Article
- The comparison of seroconversion rates among different varicella vaccines administered Turkish children; MAV/06 and vOka.Human vaccines & immunotherapeutics · 2021Article
- Estimating the basic reproductive number of varicella in South Korea incorporating social contact patterns and seroprevalence.Human vaccines & immunotherapeutics · 2021Article
- Intratracheal inoculation of human varicella zoster virus (VZV; MAV strain) vaccine successfully induced VZV IgG antibodies in rhesus monkeys.Laboratory animal research · 2021Article
- Article
- Trends in varicella and herpes zoster epidemiology before and after the implementation of universal one-dose varicella vaccination over one decade in South Korea, 2003-2015.Human vaccines & immunotherapeutics · 2019Article
- Cost-effectiveness analysis of universal varicella vaccination in Turkey using a dynamic transmission model.PloS one · 2019Article
- Increasing varicella incidence rates among children in the Republic of Korea: an age-period-cohort analysis.Epidemiology and infection · 2019Article
- Global impact of varicella vaccination programs.Human vaccines & immunotherapeutics · 2019Review
- Reply letter: trends in varicella and herpes zoster epidemiology before and after the implementation of universal one-dose varicella vaccination over one decade in South Korea, 2003-2015.Human vaccines & immunotherapeutics · 2019Article
- Vaccination history in elementary school children enrolled in the varicella epidemic investigations held in Jeju-si, Korea in the first half of 2017.Epidemiology and health · 2017Article
- Effectiveness of Varicella Vaccination Program in Preventing Laboratory-Confirmed Cases in Children in Seoul, Korea.Journal of Korean medical science · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In 2005, a single-dose varicella vaccination was incorporated into the national immunization program in Korea. Although the Oka strain is the most commonly circulating Varicella zoster virus (VZV) genotype in Korea, a domestically manufactured vaccine based on the MAV strain is widely distributed in Korea. High vaccination coverage was achieved, but breakthrough infections were frequently reported. Therefore, in this study, we aimed to analyze the maintenance of immunity after single-dose vaccination and to compare the immunity provided by the MAV and Oka vaccines. Enzyme-linked immunosorbent assays of samples from 715 vaccinated Korean children were used to assess seropositivity rates against VZV. Additionally, fluorescent-antibody-to-membrane-antigen (FAMA) tests were performed in 35 individuals in the MAV vaccine group, and seropositivity rates against the Oka strain were determined. The progressive decrease of the seropositivity rate was demonstrated from ages 1 to 4 as follows: 65% in age 1, 59% in age 2, 53% in age 3, 49% in age 4. It then increased to 62% in age 5 and 70% in age 6. Both the MAV and Oka vaccine groups showed a progressive decrease of the seropositivity rate from the age of 1 to 4 years, but the MAV vaccine group had higher seropositivity rates. In FAMA test, the MAV group demonstrated 71% seropositivity against the Oka strain. This study indicates that immunity wanes after single-dose varicella vaccination and that the MAV vaccine is not inferior to the Oka vaccine in providing immunity against VZV. The MAV vaccine also induced cross-immunity against circulating Oka strain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.